Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1998-10-30
|
| pubmed:abstractText |
The purpose of this study was to look at the efficacy and side effect profile of topiramate in a neurology unit. Using case notes, 94 patients who had been treated with topiramate were identified: 48 patients had taken part in clinical trials of topiramate, 46 received topiramate once licensed. Of these patients 24% had a greater than 50% decrease in seizure frequency. Patients with primary generalized epilepsy (n = 12) had a greater reduction in seizures compared with those with partial epilepsies (n = 70) P > 0.03. There was a high incidence (41%) of side effects, particularly psychiatric problems, leading to withdrawal of therpay in 41% of patients. Seven patients were admitted to hospital as a result of psychotic symptoms or depression. The incidence of psychotic symptoms (12%) was significantly higher for patients receiving topiramate compared with 191 patients attending the department on gabapentin (0.5%) and 270 patients attending the department on lamotrigine (0.7%) P < 0.001. 'Abnormal thinking', consisting of mental slowing and word-finding difficulties, occurred in 31%. The incidence could be significantly reduced by using 25 mg dose increments fortnightly as opposed to 100 mg weekly (P > 0.03). Although topiramate is an effective antiepileptic drug, its use is accompanied by a high incidence of particularly psychiatric side effects.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1059-1311
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
207-11
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9700833-Adolescent,
pubmed-meshheading:9700833-Adult,
pubmed-meshheading:9700833-Aged,
pubmed-meshheading:9700833-Ambulatory Care,
pubmed-meshheading:9700833-Anticonvulsants,
pubmed-meshheading:9700833-Child,
pubmed-meshheading:9700833-Cognition,
pubmed-meshheading:9700833-Depression,
pubmed-meshheading:9700833-Epilepsy,
pubmed-meshheading:9700833-Female,
pubmed-meshheading:9700833-Fructose,
pubmed-meshheading:9700833-Great Britain,
pubmed-meshheading:9700833-Hallucinations,
pubmed-meshheading:9700833-Humans,
pubmed-meshheading:9700833-Male,
pubmed-meshheading:9700833-Medical Audit,
pubmed-meshheading:9700833-Memory,
pubmed-meshheading:9700833-Middle Aged,
pubmed-meshheading:9700833-Neurology,
pubmed-meshheading:9700833-Psychoses, Substance-Induced,
pubmed-meshheading:9700833-Retrospective Studies
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
An audit of topiramate use in a general neurology clinic.
|
| pubmed:affiliation |
Department of Neurosciences, York District Hospital, UK.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|